ArticleBritish journal of pharmacology2010
Modulation of the apelin/APJ system in heart failure and atherosclerosis in man.
Article in British journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 106 citations in OpenAlex.
- Astrocytic apelin mediates cortical neuronal function and prevents anxiety-like behaviors in mice.Acta pharmacologica Sinica · 2026Article
- The Apelin-APJ Axis in Heart Failure: Mechanistic Insights, Clinical Evidence, and Translational Challenges.Cardiovascular drugs and therapy · 2026Review
- Apelin-APLNR pathway across development, inflammation, and vascular remodeling: an endothelial perspective.Experimental & molecular medicine · 2026Review
- International Union of Basic and Clinical Pharmacology. CXXI. Apelin receptor pharmacology in the human cardiovascular system and emerging clinical applications.Pharmacological reviews · 2026Review
- The Impact of the Apelinergic System on the Cardiovascular System.International journal of molecular sciences · 2025Review
- Curcumin Alleviates Doxorubicin-Induced Cardiotoxicity by Modulating Apelin Expression.Biomolecules · 2025Article
- ELABELA Ameliorates Atherosclerosis Through Restoring the M1/M2 Macrophage Balance inJournal of the American Heart Association · 2025Article
- SEC62-dependent ER-phagy contributes to apelin-13/APJ-induced monocyte-vascular endothelial cell adhesion in atherosclerosis pathogenesis.Acta pharmacologica Sinica · 2025Article
- Microparticle Mediated Delivery of Apelin Improves Heart Function in Post Myocardial Infarction Mice.Circulation research · 2024Article
- Negative association of apelin plasma levels with epicardial fat thickness in patients with stable angina and acute myocardial infarction: A case-control study.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024Article
- Targeting the apelin system for the treatment of cardiovascular diseases.Cardiovascular research · 2023Review
- Adipokines and Their Role in Heart Failure: A Literature Review.The Journal of innovations in cardiac rhythm management · 2023Review
- Apelin is expressed in intimal smooth muscle cells and promotes their phenotypic transition.Scientific reports · 2023Article
- Article
- Executable models of immune signaling pathways in HIV-associated atherosclerosis.NPJ systems biology and applications · 2022Article
- The beneficial roles of apelin-13/APJ system in cerebral ischemia: Pathogenesis and therapeutic strategies.Frontiers in pharmacology · 2022Review
- Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An Update.Clinical medicine insights. Endocrinology and diabetes · 2022Review
- Apelin and Vasopressin: The Yin and Yang of Water Balance.Frontiers in endocrinology · 2021Review
- Apelin Does Not Impair Coronary Artery Relaxation Mediated by Nitric Oxide-Induced Activation of BKFrontiers in pharmacology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeThe aim of this study was to determine whether the apelin/APJ system is altered in human cardiovascular disease by investigating whether the expression of apelin or its receptor is altered at the protein level. EXPERIMENTAL APPROACH: Radioligand binding studies were used to determine apelin receptor density in human cardiac tissues. Apelin peptide levels in cardiovascular tissues were determined by radioimmunoassay. In vitro pharmacology was used to assess vasoactive properties of apelin in human coronary artery. Localization of apelin and its receptor in coronary artery was determined using immunohistochemistry. KEY
resultsApelin receptor density was significantly decreased in left ventricle from patients with dilated cardiomyopathy or ischaemic heart disease compared with controls, but apelin peptide levels remained unchanged. Apelin was up-regulated in human atherosclerotic coronary artery and this additional peptide localized to the plaque, colocalizing with markers for macrophages and smooth muscle cells. Apelin potently constricted human coronary artery. CONCLUSIONS AND IMPLICATIONS: We have detected changes in the apelin/APJ system in human diseased cardiac and vascular tissue. The decrease in receptor density in heart failure may limit the positive inotropic actions of apelin, contributing to contractile dysfunction. The contribution of the increased apelin levels in atherosclerotic coronary artery to disease progression remains to be determined. These data suggest a potential role for the apelin/APJ system in human cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.